164 – OUTCOMES OF TOTAL KNEE ARTHROPLASTY IN PATIENTS UNDER FIFTY-FIVE

Abstract

Purpose: Total knee arthroplasty (TKA) is a proven intervention in the management of end-stage knee arthritis. However, the demands of younger, more active patients may result in increased rates of wear and aseptic loosening. The purpose of this study was to assess the long-term outcome of a large cohort of young patients, and to assess if the outcomes of cemented implants differed from non-cemented implants.

Method: Between 1984 and 2003, 350 TKAs were performed in 283 patients who were under 55 years old. Patients were followed a minimum of 5 years. Mean age at time of surgery was 49.0±5.5 years; 64% of patients were female. Primary knee pathologies included degenerative and post-traumatic arthritis (271), inflammatory arthritis (62), and others (17). Multiple implant designs were used; 296 knees were cemented and 54 were non-cemented. The Knee Society Clinical Rating Score (KSCRS) at latest follow-up was calculated. The Kaplan-Meier survivorship was calculated using an endpoint of revision total knee arthroplasty.

Results: Mean follow-up was 8.7±3.4 years. Seventeen knees were revised at a mean of 7.1±4.4 years after the index procedure. Fifteen patients (twenty-five knees) died. Fifty-one patients (sixty-two knees) were lost to follow-up. Sixty patients (sixty-seven knees) had incomplete KSCRS forms. Average function and knee domains of the KSCRS were 70.0±26.7 and 87.3±16.2 respectively. The Kaplan-Meier survival at five, ten, and fifteen years was 0.965±0.011, 0.941±0.015, and 0.933±0.017. The rate of revision was 5.9%. There was no statistically significantly difference observed between the outcomes of cemented and non-cemented implants, male and female patients, or inflammatory versus non-inflammatory arthritis.

Conclusion: This study demonstrates that total knee replacement in younger patients can demonstrate excellent survival rates free of revision. There does not appear to be an obvious survival advantage of cementless designs, or difference in outcomes based on sex of the patient or primary diagnosis of inflammatory or non-inflammatory arthritis.